Cyclerion Therapeutics Inc. (CYCN)
NASDAQ · Healthcare
Cyclerion Therapeutics Inc. EBITDA 2019–2025
Cyclerion Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2019 to 2023. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cyclerion Therapeutics Inc. ebitda for the quarter ending March 31, 2023 was -3.3 M, a 74.68% decrease year-over-year.
- Cyclerion Therapeutics Inc. ebitda for the twelve months ending March 31, 2023 was -43.0 M, a 41.42% decrease year-over-year.
- Cyclerion Therapeutics Inc. annual ebitda for 2023 was -13.0 M, a 29.90% decrease from 2022.
- Cyclerion Therapeutics Inc. annual ebitda for 2022 was -18.5 M, a 66.24% decrease from 2021.
- Cyclerion Therapeutics Inc. annual ebitda for 2021 was -54.7 M, a 30.70% decrease from 2020.
- Cyclerion Therapeutics Inc. annual ebitda for 2020 was -79.0 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cyclerion Therapeutics Inc. EBITDA — FAQ
Cyclerion Therapeutics Inc. (CYCN) ebitda over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CYCN's ebitda history?
The chart and table above show Cyclerion Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.